Regenicin (OTCMKTS:RGIN – Get Rating) and NeuroMetrix (NASDAQ:NURO – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Risk & Volatility
Regenicin has a beta of -1.89, meaning that its share price is 289% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.
Valuation & Earnings
This table compares Regenicin and NeuroMetrix’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regenicin | N/A | N/A | -$640,000.00 | N/A | N/A |
| NeuroMetrix | $8.26 million | 0.96 | -$4.42 million | ($0.63) | -1.62 |
Institutional & Insider Ownership
7.3% of NeuroMetrix shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Regenicin and NeuroMetrix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regenicin | N/A | N/A | -25.83% |
| NeuroMetrix | -65.54% | -21.96% | -20.41% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Regenicin and NeuroMetrix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regenicin | 0 | 0 | 0 | 0 | N/A |
| NeuroMetrix | 0 | 0 | 0 | 0 | N/A |
Summary
NeuroMetrix beats Regenicin on 5 of the 8 factors compared between the two stocks.
About Regenicin
Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. It intends to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. The company was founded on September 6, 2007 and is headquartered in Little Falls, NJ.
About NeuroMetrix
NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.
Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.
